- Molecular NameBumetanide
- SynonymBumetanida [INN-Spanish]; Bumetanidum [INN-Latin]
- Weight364.422
- Drugbank_IDDB00887
- ACS_NO28395-03-1
- Show 2D model
- LogP (experiment)2.6
- LogP (predicted, AB/LogP v2.0)3.11
- pka4
- LogD (pH=7, predicted)0.05
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.07
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds8
- TPSA127.1
- StatusFDA approved
- AdministrationN/A
- PharmacologyA loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective.
- Absorption_value96.0
- Absorption (description)Rapidly and completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability81.0
- Protein binding99.0
- Volume of distribution (VD)0.2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised to some extent by hydroxylation of the butyl side-chain to give the 2′-, 3′-, and 4′-alcohols; the 3′-carboxylic acid and desbutyl metabolites have also been reported.
- Half life1 h
- ExcretionAbout 50% of a dose is excreted in the urine as unchanged drug in 24 h together with 4 to 6% as the 3′-alcohol. A total of about 80% of a dose is excreted in the urine and 10% to 15% is eliminated in the faeces in 48 h.
- Urinary ExcretionN/A
- Clerance3 ml/min/kg.
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A